 |
|
Intraocular Pressure Reduction With PhXA34, a New Prostaglandin Analogue, in Patients With Ocular Hypertension
Carl B. Camras, MD;
Robert A. Schumer, MD, PhD;
Anders Marsk;
Jacqueline S. Lustgarten, MD;
Janet B. Serle, MD;
Johan Stjernschantz, MD;
Laszlo Z. Bito, PhD;
Steven M. Podos, MD
Arch Ophthalmol. 1992;110(12):1733-1738.
Abstract
| |
• In a randomized, double-masked, parallel study, one drop of 0.003% (1 µg; n=9) or 0.01% (3 µg; n=10) PhXA34, a new phenyl-substituted prostaglandin F2 analogue (13,14-dihydro-15[R,S]-17-phenyl18,19,20-trinor-prostaglandin F2-1-isopropyl ester), or its vehicle (n=10) was applied topically twice daily for 6 days to one eye in each of 29 patients with ocular hypertension. Compared with either baseline, contralateral, or vehicle control values, PhXA34 caused a significant (P<.001) dose-dependent reduction of intraocular pressure. The reduction lasted at least 12 hours after each drop and 24 to 48 hours after the last drop, with a significant (P<.0001) mean±SEM reduction of as much as 10±1 mm Hg (40%). Conjunctival hyperemia was not produced by 0.003% PhXA34, but was noted in some eyes treated with 0.01% PhXA34, and after repeated tonometry with either concentration. The prostaglandin analogue did not produce clinically obvious miosis, anterior chamber flare or cellular response, or any subjective adverse effects. PhXA34 is a potent, effective, and welltolerated ocular hypotensive agent based on our results in this small, short-term study. Its potential as a new drug for glaucoma therapy warrants further investigation in long-term, larger studies.
Author Affiliations
| |
From the Departments of Ophthalmology, Mt Sinai School of Medicine (Drs Camras, Schumer, Lustgarten, Serle, and Podos) and Columbia University College of Physicians and Surgeons, New York, NY (Dr Bito), and Kabi Pharmacia Ophthalmics, Uppsala, Sweden (Mr Marsk and Dr Stjernschantz). Dr Camras is currently in the Department of Ophthalmology, University of Nebraska Medical Center, Omaha. Drs Camras and Bito are consultants for Kabi Pharmacia Ophthalmics, and Dr Podos is a consultant for Alcon Research Laboratories, Fort Worth, Tex, and Allergan Pharmaceuticals, Irvine, Calif. Mr Marsk and Dr Stjernschantz are employees of Kabi Pharmacia Ophthalmics. Dr Bito has a proprietary interest in the development of prostaglandins and their derivatives for the treatment of ocular hypertension and glaucoma through relevant patents and patent applications that were developed, in part, under research grant EY00333 from the National Eye Institute, and were assigned, according to the National Institutes of Health directives, to the Trustees of Columbia University.
Footnotes
Accepted for publication June 11, 1992.
Presented in part at the Association for Research in Vision and Ophthalmology Annual Meeting, Sarasota, Fla, May 1, 1991.
Reprint requests to Department of Ophthalmology, University of Nebraska Medical Center, 600 S 42nd St, Omaha, NE 68198-5540 (Dr Camras).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The effect on intraocular pressure of latanoprost once or four times daily
Linden and Alm
Br. J. Ophthalmol. 2001;85:1163-1166.
ABSTRACT
| FULL TEXT
From PGF2{{alpha}}-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan The Proctor Lecture
Stjernschantz
IOVS 2001;42:1134-1145.
FULL TEXT
Mechanism related to reduction of intraocular pressure by melanocortins in rabbits
Naveh et al.
Br. J. Ophthalmol. 2000;84:1411-1414.
ABSTRACT
| FULL TEXT
A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension
Fristrom and Nilsson
Br. J. Ophthalmol. 1997;81:867-870.
ABSTRACT
| FULL TEXT
Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension
Linden et al.
Br. J. Ophthalmol. 1997;81:370-372.
ABSTRACT
| FULL TEXT
Will Latanoprost Be the 'Wonder' Drug of the '90s for the Treatment of Glaucoma?
Higginbotham
Arch Ophthalmol 1996;114:998-999.
ABSTRACT
The Effects on Aqueous Dynamics of PhXA41, a New Prostaglandin F2{alpha} Analogue, After Topical Application in Normal and Ocular Hypertensive Human Eyes
Ziai et al.
Arch Ophthalmol 1993;111:1351-1358.
ABSTRACT
Maintained Intraocular Pressure Reduction With Once-a-Day Application of a New Prostaglandin F2{alpha} Analogue (PhXA41) An In-Hospital, Placebo-Controlled Study
Racz et al.
Arch Ophthalmol 1993;111:657-661.
ABSTRACT
|
